| Bioactivity | ST91 is a α2-adrenoceptor (α2AR) agonist. ST91 activates both α2AAR and non-α2AAR subtypes to produce spinal antinociception[1][2][3]. |
| Invitro | ST91 降低 B16F10 细胞的活力、增殖和线粒体功能[2]。 |
| In Vivo | ST91 (intrathecal administration) 在大鼠体内产生抗伤害作用[1]。 |
| Name | ST91 |
| CAS | 4749-61-5 |
| Formula | C13H20ClN3 |
| Molar Mass | 253.77 |
| Appearance | Solid |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | 4°C, sealed storage, away from moisture and light *In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light) |
| Reference | [1]. Graham BA, et, al. Synergistic interactions between two alpha(2)-adrenoceptor agonists, dexmedetomidine and ST-91, in two substrains of Sprague-Dawley rats. Pain. 2000 Mar;85(1-2):135-43. [2]. Maccari S, et, al. α-Adrenoceptor stimulation attenuates melanoma growth in mice. Br J Pharmacol. 2022 Apr;179(7):1371-1383. [3]. Stone LS, et, al. ST91 [2-(2,6-diethylphenylamino)-2-imidazoline hydrochloride]-mediated spinal antinociception and synergy with opioids persists in the absence of functional alpha-2A- or alpha-2C-adrenergic receptors. J Pharmacol Exp Ther. 2007 Dec;323(3):899-906. |